Company Overview
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference across the United States, Europe, and international markets. This biotechnology enterprise operates within the Healthcare sector, specifically targeting the Biotechnology industry, which focuses on the creation of biological drugs rather than small-molecule pharmaceuticals. The company operates at a significant scale with a market capitalization of $41.26B and an annual revenue of $3.71B, supported by a workforce of 2,500 employees. These valuation and revenue figures indicate that Alnylam holds a substantial position in the market, reflecting high investor confidence and a large installed base of commercial products such as ONPATTRO and AMVUTTRA, despite the inherent risks associated with early-stage biotech development phases.
Financial Health
Alnylam reported a revenue of $3.71B for the trailing twelve months, generating a net income of $313.75M and an EBITDA of $557.24M during the same period. The substantial gap between the $3.71B revenue and the $313.75M net income reveals a cost structure where operating expenses, while high in absolute terms, are managed to preserve profitability, resulting in a profit margin of 8.4%. The company maintains a free cash flow of $128.79M, which provides the financial flexibility necessary to fund ongoing research and development without relying solely on external capital markets. Profitability is further evidenced by a gross margin of 81.6%, indicating high pricing power and low cost of goods sold relative to sales, while an operating margin of 12.0% demonstrates effective control over administrative and selling expenses. On the balance sheet, Alnylam holds $2.91B in cash against $2.97B in debt, resulting in a debt-to-equity ratio of 376.19, which suggests a highly leveraged position relative to shareholder equity. Liquidity is robust, as indicated by a current ratio of 2.76, meaning the company possesses more than double the current assets necessary to cover its short-term liabilities. Return on Equity stands at an impressive 73.3%, while Return on Assets is 6.8%, revealing that management is exceptionally effective at generating returns for shareholders relative to the equity invested, though asset efficiency is moderated by the high asset base typical of biomanufacturing.
Valuation Assessment
Valuation metrics for Alnylam include a P/E Ratio (TTM) of 133.52 and a Forward P/E of 21.61, implying that the market expects earnings growth that will eventually justify the current high multiple. The significant difference between these two figures suggests that investors anticipate a substantial compression in the trailing multiple as the company transitions to higher profitability or scales revenue further. The price-to-book ratio is 52.18, indicating a substantial market premium over the company's book value, which is common in biotechnology firms where intellectual property holds significant value not captured on standard balance sheets. Alternative valuation metrics such as a Price to Sales ratio of 11.11 and an EV/EBITDA of 74.15 suggest that the stock is priced heavily relative to its sales and cash flow generation, reflecting high expectations for future product launches. Regarding trading range, the 52-week high is $495.55 and the 52-week low is $205.87, placing the current trading price in the upper-middle portion of this historical range. The stock exhibits a Beta of 0.38, which indicates that price volatility is significantly lower than the broader market, suggesting the asset may be less sensitive to general market fluctuations compared to large-cap equities.
Growth & Income
Revenue growth for the company is 84.9% year-over-year, while earnings growth is N/A, indicating that while top-line expansion is accelerating rapidly, the calculation of year-over-year earnings growth may be impacted by non-recurring items or base effects in the prior period. Since earnings growth data is unavailable, it is not possible to determine if earnings are growing faster or slower than revenue at this specific moment, but the massive revenue expansion often precedes normalized earnings performance in the biotech lifecycle. The company does not pay a dividend, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning the firm reinvests all net income back into operations and research rather than distributing cash to shareholders. This profile of aggressive revenue growth combined with a zero dividend payout characterizes Alnylam as a growth-oriented investment vehicle that prioritizes capital allocation toward developing new therapies over providing income to investors.